ºñ¼Ò¼¼Æ÷¼ºÆä¾Ï¿¡¼­ ¹æ»ç¼±Ä¡·á´Üµ¶¿ä¹ý°ú Ç×¾ÏÁ¦ º´ÇÕ¿ä¹ý°úÀÇ Ä¡·á°á°ú ºñ±³
Therapeutic Results of Radiation Therapy Alone and Combination with Chemotherapy in Non-Small Cell Lung Carcinoma

´ëÇÑÄ¡·á¹æ»ç¼±°úÇÐȸÁö 1993³â 11±Ç 2È£ p.303 ~ p.309

±èÁÖ¸®(Kim Ju-Ree) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¹éº´¿ø Ä¡·á¹æ»ç¼±°úÇб³½Ç
¼­Çö¼÷(Suh Hyun-Suk) - ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ¼­¿ï¹éº´¿ø Ä¡·á¹æ»ç¼±°úÇб³½Ç

Abstract

Between November 1983 and December 1992, 121 patients with non-small cell lung cancer were treated with radiotherapy alone or combined with chemotherapy in Inje University, Seoul Paik Hospital.
Of these, 97 patients were evaluable and analyzed retrospectively. Group 1(n=62) was treated with radiotherapy alone and group 2(n=35) combined with chemotherapy. There were 7 patients, 1 patient with stage I and ¥±, 20 patients, 11 patients with stage ¥²A, 28 patients,20 patients with stage ¥²B, and 6 patients, 3 patients with stage IV, respectively. Ninety percent of patients received more than 5000 cGy of radiaton.
Median survival of patients in group 1 was 9 months, group 2 was 15 months. Overall 2 year survival rates of group 1 and 2 were 37% and 27%, respectively. Relapse free survival rates at 2 year were 27% and 15%, respectively. Overall survival rates at 5 year for group 1 and 2 were 15% and 11%, and relapse free survival rates were 16% and 6%, respectively.
Median survival of complete and partial responders was 17 months in group 1, 18 Months in group 2, and those of stable or progression was 6 mouths, 11 months, respectively.
The proportion of locoregional relapse and distant metastasis was not significantly different between group 1 and 2. The majority of relapse developed within 2 years.
Although 2 cases of severe esophagitis and myelosuppression were noted in group 2, the treatment related toxicity was relatively acceptable.
Our analysis showed no statistically significant differences between the two treatment groups in terms of response rate, survival, and sites of relapse.

Å°¿öµå

Non-small cell lung carcinoma, Radiotherapy alone, Combined modality with radiotherapy and chemotherapy
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
No statistically significant differences between the two treatment groups in terms of response rate, survival, and sites of relapse.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå